Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 235

1.

An unusual association of CANOMAD and rheumatoid arthritis with a long-term follow-up.

Toussirot E, Bereau M, Sevrin P, Tatu L.

Joint Bone Spine. 2019 Sep 23. pii: S1297-319X(19)30139-3. doi: 10.1016/j.jbspin.2019.09.009. [Epub ahead of print] No abstract available.

PMID:
31557526
2.

Pharmacological management of axial spondyloarthritis in adults.

Toussirot E.

Expert Opin Pharmacother. 2019 Aug;20(12):1483-1491. doi: 10.1080/14656566.2019.1617853. Epub 2019 May 16. Review.

PMID:
31095430
3.

Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis.

Toussirot E, Bernard C, Bossert M.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):344-345. Epub 2019 Mar 7. No abstract available.

4.

MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?

Toussirot E, Saas P.

RMD Open. 2018 Dec 28;4(2):e000821. doi: 10.1136/rmdopen-2018-000821. eCollection 2018. No abstract available.

5.

Anti-neutrophil cytoplasmic antibody-associated chronic inflammatory arthritis without vasculitis. Data from a French nationwide survey.

Carvajal Alegria G, Groh M, Guellec D, Toussirot E, Rigaud J, Soubrier M, Ottaviani S, Direz G, Saraux A, Cornec D; CRI (Club Rhumatisme et inflammation).

Autoimmun Rev. 2018 Dec;17(12):1268-1269. doi: 10.1016/j.autrev.2018.07.005. Epub 2018 Oct 12. No abstract available.

PMID:
30316986
6.

Unilateral Accessory Sacroiliac Joint with Bone Marrow Edema Mimicking Sacroiliitis.

Toussirot E, Aubry S, Runge M.

J Rheumatol. 2018 Aug;45(9):1327-1328. doi: 10.3899/jrheum.180030. No abstract available.

PMID:
30173180
7.

Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis.

Toussirot É, Laheurte C, Gaugler B, Gabriel D, Saas P.

Front Immunol. 2018 Jul 13;9:1610. doi: 10.3389/fimmu.2018.01610. eCollection 2018.

8.

Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence.

Toussirot E, Béreau M, Vauchy C, Saas P.

Front Physiol. 2018 Apr 24;9:440. doi: 10.3389/fphys.2018.00440. eCollection 2018. Review.

9.

Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.

Toussirot E.

Expert Opin Biol Ther. 2018 Jan;18(1):101-107. doi: 10.1080/14712598.2018.1410133. Epub 2017 Nov 29. Review.

PMID:
29187009
10.
11.

Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis.

Saas P, Bonnefoy F, Toussirot E, Perruche S.

Front Immunol. 2017 Oct 9;8:1191. doi: 10.3389/fimmu.2017.01191. eCollection 2017. Review.

12.

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

Toussirot E, Marotte H.

RMD Open. 2017 Sep 12;3(2):e000492. doi: 10.1136/rmdopen-2017-000492. eCollection 2017. No abstract available.

13.

Serum adipokines, adipose tissue measurements and metabolic parameters in patients with advanced radiographic knee osteoarthritis.

Toussirot E, Michel F, Béreau M, Dehecq B, Gaugler B, Wendling D, Grandclément E, Saas P, Dumoulin G.

Clin Rheumatol. 2017 Nov;36(11):2531-2539. doi: 10.1007/s10067-017-3789-0. Epub 2017 Aug 22.

PMID:
28831581
14.

Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.

Mekinian A, Dervin G, Lapidus N, Kahn JE, Terriou L, Liozon E, Grignano E, Piette JC, Rauzy OB, Grobost V, Godmer P, Gillard J, Rossignol J, Launay D, Aouba A, Cardon T, Bouillet L, Broner J, Vinit J, Ades L, Carrat F, Salvado C, Toussirot E, Versini M, Costedoat-Chalumeau N, Fraison JB, Guilpain P, Fenaux P, Fain O; GFM, SNFMI, CRI and MINHEMON.

Autoimmun Rev. 2017 Sep;16(9):903-910. doi: 10.1016/j.autrev.2017.07.003. Epub 2017 Jul 10.

PMID:
28705782
15.

New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.

Toussirot E.

Expert Opin Pharmacother. 2017 Feb;18(3):275-282. doi: 10.1080/14656566.2017.1284793. Epub 2017 Jan 27. Review.

PMID:
28099816
16.

Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

Toussirot É, Régent A, Devauchelle-Pensec V, Saraux A, Puéchal X.

RMD Open. 2016 Aug 31;2(2):e000305. eCollection 2016. No abstract available.

17.

Apoptotic cell infusion treats ongoing collagen-induced arthritis, even in the presence of methotrexate, and is synergic with anti-TNF therapy.

Bonnefoy F, Daoui A, Valmary-Degano S, Toussirot E, Saas P, Perruche S.

Arthritis Res Ther. 2016 Aug 11;18(1):184. doi: 10.1186/s13075-016-1084-0.

18.

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Toussirot É, Aubin F.

RMD Open. 2016 Jul 15;2(2):e000239. doi: 10.1136/rmdopen-2015-000239. eCollection 2016. Review.

19.

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials.

Toussirot E, Vauchy C, Binda D, Michel F.

Drug Des Devel Ther. 2016 Jul 1;10:2087-94. doi: 10.2147/DDDT.S107587. eCollection 2016. Review. Erratum in: Drug Des Devel Ther. 2017 Jan 11;11:175.

20.

New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases.

Méry-Bossard L, Bagny K, Chaby G, Khemis A, Maccari F, Marotte H, Perrot JL, Reguiai Z, Sigal ML, Avenel-Audran M, Boyé T, Grasland A, Gillard J, Jullien D, Toussirot E.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):181-186. doi: 10.1111/jdv.13759. Epub 2016 Jun 13.

PMID:
27291924

Supplemental Content

Loading ...
Support Center